Renowned Biotech Leader Dr. Vincent Ling Joins Morphocell Technologies as Chief Business Officer

Montreal, QC, August 5, 2024 – Morphocell Technologies Inc., a leading regenerative medicine start-up, is excited to announce the appointment of Dr. Vincent Ling as its new Chief Business Officer. Dr. Ling will lead the company’s business development activities to advance the development of its tissue engineering and cell therapy platform.

​

Dr. Ling is a world-class leader with thirty years of experience in biotech and pharma innovation. Based in the Boston and Cambridge area, he has a rare and extensive scientific and business development background at the frontier of cell therapy, biologics, genetic engineering, novel biomaterials and cellular bio-delivery systems.

He held leadership and executive positions in leading biotechnology companies, including Genetics Institute (now Wyeth), Adnexus Therapeutics and Neurotech Pharmaceuticals. Dr. Ling joins Morphocell after 12 years at Takeda Pharmaceuticals, where he was in charge of identifying, financing and developing early-stage pipelines across therapeutic areas and billion-dollar franchises. Among many successful projects, he identified and supported the Kariko-Weissman mRNA vaccine technology from University of Pennsylvania, which subsequently evolved into the first COVID mRNA vaccine and resulted in the 2023 Nobel Prize in Physiology and Medicine. Over the years, he focused on several therapeutic indications, including liver diseases, always keeping the patient at the center of any strategic decisions. Dr. Ling is an advisor for the Gates Foundation and several academic and non-profit institutions, and a prolific communicator on scientific, biotech and pharma affairs. He holds degrees from U.C. Berkeley (BA), University of Illinois (MS, Ph.D.), and post-doctoral work at Harvard University.

"I am honored to join Morphocell’s team in creating a bioengineered therapy to address liver diseases. I am impressed with Morphocell’s quality of science, which is aligned with an unwavering clinical focus.  Morphocell's integrated approach to developing ReLiver will offer a practical solution for patients suffering from liver failure." said Dr. Ling. " I am excited to expand Morphocell’s unique presence in biopharma with future collaborative research programs and technology partnerships."

Dr. Massimiliano Paganelli, co-founder and CEO of Morphocell Technologies, said, "We're excited to welcome Dr. Ling to our team. Vincent's unparalleled expertise and visionary leadership in the biotech and pharmaceutical industries make him an invaluable addition to our executive team. His remarkable track record of pioneering advancements at the cutting edge of therapeutics always keeping the patient’s needs as the sole true goal aligns perfectly with our mission at Morphocell. We are thrilled to have him onboard to steer our business development initiatives and drive our innovative platform to new heights," said Dr. Massimiliano Paganelli, CEO of Morphocell Technologies Inc."